[1] Khan ZU,Randhawa HS,Kowshik T,et al.Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India[J].J Antimicrob Chemother,2007,60(2):312-316.
[2] Souza LK,Fernandes Ode F,Kobayashi CC,et al.Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiania city,Goias,Brazil[J].Rev Inst Med Trop San Paulo,2005,47(5):253-256.
[3] Khan ZU,Randhawa HS,Chehadeh W,et al.Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole[J].Int J Antimicrob Agents,2009,33(6):559-563.
[4] Okabayashi K,Imaji M,Osumi T,et al.Antifungal activity of itraconazole and voriconazole against clinical isolates obtained from animals with mycoses[J].Nippon Ishinkin Gakkai Zasshi,2009,50(2):91-94.
[5] Pfaller MA,Zhang J,Messer SA,et al.In vitro activities of voriconazole,fluconazole,and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa[J].Antimicrob Agents Chemother,1999,43(1):169-171.
[6] Hoban DJ,Zhanel GG,Karlowsky JA.In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients[J].Antimicrob Agents Chemother,1999,43(6):1463-1464.
[7] Mitsuyama J,Nomura N,Hashimoto K,et al.In vitro and in vivo antifungal activities of T-2307,a novel arylamidine[J].Antimicrob Agents Chemother,2008,52(4):1318-1324.
[8] Pfaller MA,Diekema DJ,Gibbs DL,et al.Results from the ARTEMIS DISK Global Antifungal Surveillance Study,1997 to 2007:10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and variconazole determined by CLSI standardized disk diffusion testing[J].J Clin Microbial,2009,47(1):117-123.
[9] Chandenier J,Adou-Bryn KD,Douchet C,et al.In vitro activity of amphotericin B,fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia[J].Eur J Clin Microbiol Infect Dis,2004,(6):506-508.
[10] Perkins A,Gomez-Lopez A,Mellado E,et al.Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var.neoformans[J].J Antimicrob Chemother,2005,56(6):1144-1147.
[11] Thompson GR,Wiederhold NP,Fothergill AW,et al.Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans[J].Antimicrob Agents Chemother,2009,53(1):309-311.
[12] Yildiran ST,Fothergill AW,Sutton DA,et al.In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole,voriconazole and posaconazole(SCH56592)[J].Mycoses,2002,45(9-10):378-383.
[13] Ana KF,Costa JJC,Sidrim RA.Urban Pigeons(Columba livia)as a Potential Source of Pathogenic Yeasts:A Focus on Antifungal Susceptibility of Cryptococcus Strains in Northeast Brazil[J].Mycopathologia,2010,169(3):207-213.
[14] Patrick Schwarz.In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates[J].Antimicrob Agents Chemother,2003,3:3361-3364.
[15] Chang WN,Huang CR,Lei CB,et al.Serotypes of elinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphoteriein B,flueonazole,and voriconazole[J].Jpn J Infect Dis,2004,57(3):113-115.
[16] Souza LK,Fernandes Ode F,Kobayashi CC,et al.Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiania city,Goias,Brazil[J].Rev lnst Med Trop San Paulo,2005,47(5):253-256.
[17] Hagen F,lllnait-Zaragozi MT,Bartlett KH,et al.In vitro antifungal susceptibilities and AFLP genotyping of a worldwide collection of 350 clinical,veterinary and environmental Cryptococcus gattii isolates.Antimicrob Agents Chemother,2010 Sep 20[Epub ahead of print].
[18] Martinez LR,Ntiamoah P,Gacser A,et al.Voriconazole inhibits melanization in Cryptococcus neoformans[J].Antimi-crob Agents Chemother,2007,51(12):4396-4400.
[19] van Duin D,Cleare W,Zaragoza O,et al.Effects of voriconazole on Cryptococcus neoformans[J].Antimicrob Agents Chemother,2004,48(6):2014-2020.
[20] Chiller T,Farrokhshad K,Brummer E,et al.Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils,monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans[J].Med Mycol,2002,40(1):21-26.
[21] Kirkpatrick WR,Najvar LK,Bocanegra R,et al.New guinea pig model of cryptococcal meningitis[J].Antimicrob Agents Chemother,2007,51(8):3011-3013.
[22] Serena C,Pastor FJ,Matine M,et al.Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection[J].J Antimicrob Chemother,2007,60(1):162-165.
[23] Mavrogiorgos N,Zaragoza O,Casadevall A,et al.Efficacy of voriconazole in experimental Cryptococcus neoformans infection[J].Mycopathologia,2006,162(2):111-114.
[24] Silva EG,Paula CR,Dias AL,et al.Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans[J].Mycopathologia,2010 Oct 24[Epub ahead of print].
[25] Cairo E,Pastor FJ,Rodriguez MM,et al.Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii[J].Antimicrob Agents Chemother,2010,54(10):4074-4077.
[26] Perfect JR,Marr KA,Walsh TJ,et al.Voriconazole treatment for less common,emerging,or refractory fungal infections[J].Clin Infect Dis,2003,36:1122-1131.
[27] Sabbatani S,Manfredi R,Pavoni M,et al.Voriconazole proves effective in long-term treatment of a cerebra] cryptococcoma in a chronic nephropathic HIV-negative patient,after fluconazole failure[J].Mycopathologia,2004,158(2):165-171.
[28] Izumikawa K,Zhao Y,Motoshima K,et al.A case of pulmonary cryptococcosis fullowed by pleuritis in an apparently immunecompetent patient during fluconazole treatment[J].Med Mycol,2008,46(6):595-599.
[29] Tschudin S,Elzi L,Mayr M,et al.Successful treatment of cryptococcal meningitis with voriconazole in a kidney transplant recipient[J].Int J Infect Dis,2006,10(3):17.
[30] Carbonara S,Regazzi M,Ciracl E,et al.Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis[J].Ann Pharmacother,2009,43(5):978-984.
[31] Bandettini R,Castagnola E,Calvillo M,et al.Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant[J].J Chemother,2009,21(1):108-109.
[32] Jose IV,Jesus DC,Ferran S,et al.Management of endogenous cryptococcal endophthalmitis with voriconazole[J].Can J Ophthalmol,2009,44(6):e61-62.
[33] Lu HZ.Voriconazole in an infant with cryptococcal meningitis[J].Chin Med J,2008,121(3):286-288.
[34] 朱一飞,邹月丽,王敏,等,伏立康唑治疗隐球菌性脑膜炎三例报告[J].脑与神经疾病杂志,2008,16(6):669-670.
[35] Saag MS,Graybill RJ,Larsen RA,et al.Practice Guidelines for the Management of Cryptococcal Disease[J].Clin Infect Dis,2000,30(4):710-718. |
